Article Information
History
- August 29, 2021.
Article Versions
- Version 1 (July 30, 2021 - 21:37).
- Version 2 (August 17, 2021 - 03:16).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Nanaka Kaneshiro1,2,
- Masato Komai1,
- Ryosuke Imaoka1,
- Atsuya Ikeda1,
- Yuji Kamikubo4,
- Tadafumi Hashimoto3,
- Takeshi Iwatsubo3,
- Takashi Sakurai4,
- Takashi Uehara1 and
- Nobumasa Takasugi1,4,*
- 1Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
- 2Research Fellow of Japan Society for the Promotion of Science, Chiyoda-ku, Tokyo 102-0083, Japan
- 3Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
- 4Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
- ↵* Correspondence should be addressed to - Nobumsa Takasugi, Ph.D., Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan, email: ntakasu{at}okayama-u.ac.jp, tel & fax+81-86-251-7985
Posted August 29, 2021.
Lipid flippase dysfunction as a novel therapeutic target for endosomal anomalies in Alzheimer’s disease
